Prabhudas Lilladher's research report on Jupiter Life Line Hospitals
JLHL’s Q2 consolidated EBITDA adjusted for one offs grew by 9% YoY to Rs850mn. Its operational efficiency has been strong in the competitive markets of MMR. The company reported revenue/EBITDA CAGR of 20%/25% over FY22-25. Given its expansion plans, scale-up in occupancy and improving margins, growth momentum is expected to sustain over the medium term. We believe strategic greenfield expansions in densely populated micro-markets of western regions will drive sustainable growth. Our FY27E and FY28E EBITDA stands reduced by 3-5% as we factor in lower margins. Overall, we see 19%/14% CAGR in EBITDA/PAT over FY25-28E with healthy return ratios of ~16%.
Outlook
Maintain ‘BUY’ rating with a TP of Rs1,800/share, valuing at 26x EV/EBITDA based on Sept 2027E EBITDA as we roll forward.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Jupiter Life Line Hospitals - 13112025 - prabhu